Gennexa, a firm specializing in AI-driven business process automation, has secured the 'Most Innovative AI-Powered Intelligent Operations Company – UAE 2026' title from Global Elite Business Magazine. The award recognizes the company’s integration of autonomous agents and human oversight to streamline complex enterprise workflows across international markets.
Nearly 200 officials and business leaders gathered in Kuala Lumpur on July 30 for the 2026 Land-Sea Economic Forum, seeking to integrate artificial intelligence into the New International Land-Sea Trade Corridor. The session focused on shifting from mere market entry to deep industrial localization across ASEAN markets.
Shareholders who acquired Photronics, Inc. stock between December 10, 2025, and May 27, 2026, have until September 4, 2026, to join a pending class action lawsuit. The litigation, led by Schall Brown & Schwartz LLP, alleges the company misled investors regarding its revenue growth and operational capabilities.
London-based biotechnology firm MOYOM has secured EU MDR certification for its APHRANEL® injectable, marking a significant entry point into the European regenerative aesthetics market. To bolster its clinical credibility, the company has simultaneously launched a strategic scientific partnership with Dr. Patrick Trévidic and his firm, Expert2Expert.
Investors who purchased Futu Holdings Limited stock between May 24, 2023, and May 27, 2026, are being urged to join a class action lawsuit. The litigation targets alleged violations of the Securities Exchange Act, specifically focusing on the company's failure to maintain regulatory standards mandated by the China Securities Regulatory Commission.
Portland General Electric reported second-quarter net income of $68 million, or $0.59 per diluted share, as the utility navigated shifting demand patterns. The company’s financial performance remained aligned with its 2026 guidance, buoyed by an 11% surge in industrial energy consumption driven primarily by high-tech firms and data centers.
London-based biotechnology firm MOYOM has secured European Medical Device Regulation certification for its APHRANEL injectable, signaling a major entry into the European regenerative aesthetics market. The company simultaneously launched a strategic partnership with Expert2Expert, led by renowned surgeon Dr. Patrick Trévidic, to anchor the product’s rollout in rigorous clinical research.
Investors are looking toward Beijing as Baidu prepares to unveil its financial performance for the second quarter of 2026. The AI giant confirmed it will release its results before the U.S. markets open on August 18, setting the stage for a critical update on its ongoing transition toward artificial intelligence.
A 62-meter concrete pump truck delivery to Panama-based Ital Concretos marks a strategic shift for Zoomlion, as repeat orders now drive the manufacturer's international expansion. By prioritizing local service infrastructure alongside equipment performance, the Chinese firm is converting initial trial purchases into long-term fleet partnerships.
Kuaishou Technology will release its unaudited financial results for the second quarter and the first half of 2026 on August 19. The social platform plans to host a conference call following the close of the Hong Kong market to detail its performance and operational milestones from the first six months of the year.
Investors who purchased Futu Holdings Limited securities between May 24, 2023, and May 27, 2026, have until August 25 to apply as lead plaintiffs in a pending class action lawsuit. The litigation targets alleged misrepresentations regarding the company’s regulatory compliance and business practices within mainland China.
Investors who purchased Peabody Energy Corporation common stock between October 14, 2024, and May 4, 2026, face an August 24, 2026, deadline to seek appointment as lead plaintiff in a pending securities fraud class action lawsuit currently moving through the court system.
With an August 4, 2026, deadline approaching, shareholders who purchased PicS N.V. stock following the company's January IPO are weighing a class action lawsuit. Schall, Brown & Schwartz LLP is currently organizing the litigation, targeting alleged violations of federal securities laws stemming from misrepresented credit evaluation procedures.
Investors who purchased BitGo Holdings, Inc. stock following its January 2026 initial public offering face a critical window to join a securities fraud class action. Schall, Brown & Schwartz LLP is currently seeking lead plaintiffs for the lawsuit, which alleges the company misled the market regarding digital asset risks.
With a deal worth up to 423.5 million euros, Shanghai-based IMPACT Therapeutics has granted Pharmanovia exclusive rights to develop and distribute its PARP inhibitor, senaparib, across 66 countries. The partnership marks the biotech firm's first major strategic push to bring its oncology portfolio to markets outside of China.
Investors who incurred financial losses holding Seer, Inc. stock are now under scrutiny by the national litigation firm Schall, Brown & Schwartz. The legal group has opened a formal investigation into potential securities law violations, specifically examining whether the company released misleading information or suppressed data critical to its shareholders.
A class action lawsuit alleges Wix.com Ltd. deceived shareholders by inflating the capabilities of its AI tools while obscuring the true costs of development. The litigation, filed in Los Angeles, targets statements made by the company between February 19, 2025, and May 12, 2026, regarding its competitive market standing.
Investors who held Wix.com Ltd. stock between February 19, 2025, and May 12, 2026, face a critical deadline of September 22, 2026, to join a class action lawsuit. Schall, Brown & Schwartz LLP is currently seeking lead plaintiffs to represent those who suffered financial losses due to the company's alleged market misconduct.
A national shareholder rights firm, Schall, Brown & Schwartz LLP, has launched an investigation into the Columbia Dividend Income Fund, traded as GSFTX. The inquiry centers on allegations that the fund issued misleading statements or withheld critical financial information from its investors, potentially violating federal securities laws.
Investors who purchased GeneDx Holdings Corp. stock between April 16, 2025, and May 4, 2026, face an August 3, 2026, deadline to join a class action lawsuit. The litigation alleges the company violated the Securities Exchange Act by issuing false statements regarding its financial health and earnings outlook.
Investors who purchased Hub Group, Inc. stock between April 28, 2023, and May 11, 2026, are being urged to join a class action lawsuit. The complaint alleges that the logistics firm misled the market by filing financial statements containing material errors regarding revenue recognition and operating income.
Shareholders of PROCEPT BioRobotics face a potential recovery path following a class action lawsuit alleging the company misled investors through aggressive accounting practices. The litigation focuses on claims that the firm artificially inflated revenue figures by pulling sales forward, creating a significant inventory glut between 2024 and 2026.
Investors who purchased Hub Group, Inc. securities between April 28, 2023, and May 11, 2026, face an August 28, 2026, deadline to seek lead plaintiff status in a pending class action lawsuit. The litigation targets alleged violations of the Securities Exchange Act, specifically regarding misleading financial disclosures.
Investors who purchased Photronics, Inc. shares between December 10, 2025, and May 27, 2026, face a critical window to join a class action lawsuit. The DJS Law Group is currently organizing the case, which centers on allegations that the company issued false statements regarding its product pipeline and financial momentum.
Investors who purchased Planet Fitness, Inc. common stock between November 6, 2025, and May 6, 2026, have until September 14, 2026, to file as lead plaintiffs in a pending securities fraud class action. The lawsuit alleges the company misled shareholders regarding its marketing efficacy and core customer acquisition metrics.
Shanghai-based IMPACT Therapeutics has secured an exclusive licensing deal with Pharmanovia to distribute its PARP inhibitor, senaparib, across 66 countries. The partnership targets maintenance therapy for advanced ovarian, fallopian tube, and primary peritoneal cancers, marking the biotech firm's first major commercial expansion beyond the Chinese market.
Shareholders who acquired Erasca, Inc. stock between January 14, 2025, and April 26, 2026, face an August 10 deadline to join a class action lawsuit. The litigation, spearheaded by Schall, Brown & Schwartz LLP, alleges the company misled the market regarding the clinical viability of its ERAS-0015 drug candidate.
Investors who purchased Roblox Corporation shares between October 30, 2025, and April 30, 2026, are being urged to join a class action lawsuit. The litigation targets the gaming giant for allegedly misleading the market regarding the financial impact of its age verification policies on long-term growth.
Investors who purchased ADMA Biologics shares between August 9, 2024, and March 25, 2026, face a critical August 10, 2026, deadline to seek lead plaintiff status in a class action lawsuit. The litigation, filed by Schall, Brown & Schwartz LLP, targets alleged violations of the Securities Exchange Act of 1934.
Hanon Systems reported a second-quarter operating profit of KRW 103.7 billion, signaling a recovery driven by structural cost-cutting and a surge in electrification demand. The automotive thermal management supplier, now a subsidiary of Hankook & Company Group, posted quarterly revenue of KRW 2.87 trillion, stabilizing its financial position after recent global shifts.
